文献速递胃肠动力与功能性疾病

团体认知行为治疗联合内感受暴露治疗药物难治性肠易激综合征:一项随机对照试验

Group Cognitive-Behavioral Therapy With Interoceptive Exposure for Drug-Refractory Irritable Bowel Syndrome: A Randomized Controlled Trial.
PubMed 文献 · Am J Gastroenterol · 2022-01-01

该单中心、开放标签随机对照试验纳入114例药物难治性肠易激综合征患者,按1:1分为10周团体认知行为治疗联合内感受暴露组(GCBT-IE组,n=54)与等待名单组(WL组,n=60)。第13周时,GCBT-IE组在IBS症状严重程度评分和生活质量量表上的改善均优于WL组。作者认为GCBT-IE是药物难治性IBS有效、安全且高效的治疗选择。

要点

  • GCBT-IE组IBS症状严重程度评分较基线变化为-115.8,WL组为-29.7,组间差异为-86.1(95%CI -117.3至-55.0)。
  • GCBT-IE组IBS生活质量量表较基线变化为20.1,WL组为-0.2,组间差异为20.3(95%CI 15.2至25.3)。
  • 报告6例非预期严重不良事件,经判定与干预措施无关。

核心结论

  • GCBT-IE是药物难治性肠易激综合征患者有效、安全且高效的治疗选择。

研究设计与样本

  • 单中心、开放标签、随机对照试验,在日本开展,纳入年龄18-75岁、中度至重度药物难治性肠易激综合征患者。
  • 参与者按IBS严重程度分层,由独立工作人员以区组随机化按1:1分配至10周GCBT-IE组或等待名单(WL)组。
  • 两组均进行自我监测并接受常规治疗。
  • 共114例患者被随机分配至GCBT-IE组(n=54)或WL组(n=60)。
  • 主要结局为基线至第13周IBS症状严重程度评分和IBS生活质量量表(IBS-QOL)的变化,在意向性治疗样本中评估。

主要发现

  • GCBT-IE组49例(90.7%)和WL组58例(96.7%)完成了第13周评估。
  • GCBT-IE组IBS症状严重程度评分较基线变化为-115.8,WL组为-29.7,组间差异为-86.1(95%CI -117.3至-55.0)。
  • GCBT-IE组IBS-QOL较基线变化为20.1,WL组为-0.2,组间差异为20.3(95%CI 15.2至25.3)。
  • 报告6例非预期严重不良事件,经判定与干预措施无关。

临床怎么用

  • 作者认为,GCBT-IE是药物难治性肠易激综合征患者有效、安全且高效的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Few people can access psychotherapy for irritable bowel syndrome (IBS). Group cognitive-behavioral therapy (GCBT) may be efficient, but the evidence for its efficacy is weak and limited. We aimed to assess the efficacy and safety of GCBT with interoceptive exposure (GCBT-IE), a novel form of GCBT for drug-refractory IBS. METHODS: A single-center, open-label, randomized, controlled trial was conducted in Japan among people aged 18-75 years with moderate-to-severe drug-refractory IBS. Participants were stratified by IBS severity and allocated 1:1 to 10-week GCBT-IE or waiting list (WL) in a blockwise randomization by independent staff. Both arms practiced self-monitoring and received treatment as usual. Multiple primary outcomes were changes from baseline to week 13 in the IBS Symptom Severity Score and the IBS Quality of Life Measure (IBS-QOL), assessed in the intention-to-treat sample. RESULTS: A total of 114 people with drug-refractory IBS were randomized to GCBT-IE (n = 54) or WL (n = 60). Forty-nine participants (90.7%) in the GCBT-IE arm and 58 (96.7%) in the WL arm completed the week 13 assessment. Participants in the GCBT-IE arm reported greater improvements in both IBS symptom severity and quality of life compared with the WL arm, with -115.8 vs -29.7 on the IBS Symptom Severity Score (a difference of -86.1, 95% confidence interval -117.3 to -55.0), and 20.1 vs -0.2 on the IBS-QOL (a difference of 20.3, 95% confidence interval 15.2-25.3), respectively. Six unexpected serious adverse events were reported but were judged as unrelated to the interventions. DISCUSSION: GCBT-IE is an efficacious, safe, and efficient treatment option for people with drug-refractory IBS.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Kikuchi S, Oe Y, Ito Y, et al. Group Cognitive-Behavioral Therapy With Interoceptive Exposure for Drug-Refractory Irritable Bowel Syndrome: A Randomized Controlled Trial. Am J Gastroenterol. 2022. PMID: 35103022. doi:10.14309/ajg.0000000000001664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。